Reflections from the Summer Diabetes conferences: ADA 2024 and ADCES 2024

Advancing Diabetes Care Through Innovation and Collaboration

Following tradition from last year, I'm excited to share my experience at the 84th Scientific Sessions of the American Diabetes Association (ADA), held in Orlando, FL, from June 21st to June 24th. This year, Rimidi also attended the American Diabetes Care and Education Specialists meeting in New Orleans from August 9th through 12th.

This year's conferences united pioneers in diabetes care, technology, and patient advocacy, offering a pivotal stage to exchange the newest research and innovations.

Strengthening Partnerships and Collaborations

We continue to expand our engagements with several of our diabetes technology partners, including Abbott, Dexcom, and Senseonics. The approval of over-the-counter continuous glucose monitors starting in the Spring with Dexcom’s Stelo and followed this Summer with Abbott’s Lingo and Rio has clinicians and diabetes advocates discussing the impact that expanded access to CGM will have on patient outcomes and the diabetes technology market.

While a smaller percentage of the CGM market, Senseonics announced key milestones for its implantable CGM (approval in April to connect with insulin pumps and submission for approval of its 365-day implantable CGM with reduced calibration requirements. The team discussed the upcoming demonstration project with Rimidi at Mercy in St. Louis. Collectively, these innovations further expand options for people living with diabetes (and now prediabetes and metabolic syndrome) to track glucose levels and better understand and manage their health.

Rimidi also highlighted our partnerships in innovative diabetes care delivery models. Our partners at Tenovi attended the ADA meeting with us to showcase their remote patient monitoring devices such as connected blood glucose meters, scales, blood pressure cuffs and medication adherence technologies. With a demonstrated impact on outcomes, RPM will continue to grow as an important means of monitoring and managing diabetes.

Building on the technology innovations powering the growth of RPM, Rimidi and Quest Health RPM attended ADCES together to discuss innovative care delivery models. Quest is part of the Rimidi Care Network partner program that brings outsourced clinical monitoring to practices that need both expertise and staffing assistance with their RPM program. Quest’s wealth of experience with continuous glucose monitoring makes them a unique partner to complement Rimidi’s software expertise and extensive technology integrations.

Key Themes at ADA and ADCES

Both in the Scientific Sessions and on the show floor, it felt like this year’s ADA and ADCES meetings continued to build on key themes from 2023.

1. GLP-1s, obesity, weight loss, and cardiometabolic outcomes: Just like you can’t watch cable television without seeing an ad for Ozempic, GLP-1s were the unavoidable topic on the expo floor, in scientific sessions and really everywhere you looked. Data was presented on the impact of GLP-1s on everything from blood pressure to cardiovascular risk to lipid control to kidney function and of course weight management. We expect this to stay at the top of the list for these meetings for years to come.
2. Disparities in diabetes care: Addressing health inequities and improving diabetes care for underserved populations also continued to be a critical theme. Efforts to reduce disparities and enhance access to care were highlighted in poster sessions and scientific presentations. Innovative care delivery models, culturally competent care and more affordable technologies will all continue to impact this issue.
3. Advancements in technology and AI: Other than GLP-1s (see item #1), diabetes technologies really dominated the expo floors at both of these meetings in a way they did not 4-5 years ago. In addition to the CGM advancements discussed above, new pump technologies such as Twiist and automated insulin delivery systems were driving traffic to booths for demonstrations and to scientific sessions for presentations about the impact on time in range and outcomes.

Rimidi’s Ongoing Commitment

Rimidi was founded on the basis of driving better outcomes for patients living with diabetes. While we have expanded our platform to support additional chronic diseases to address the need to manage patients with multiple comorbidities as well as to streamline platforms for health systems and clinics needing to support multiple service lines, we remain dedicated to our roots. Our ongoing efforts to build out the portfolio of devices with which we integrate reflect this commitment. Look for insulin pumps and insulin pens as an area we will continue to grow.

Attending the ADA Conference reinforced Rimidi’s dedication to integrating state-of-the-art technologies and the most recent scientific evidence to improve patient care. By partnering with industry leaders and staying engaged with the latest advancements, we are committed to driving better health outcomes for patients with diabetes and other chronic conditions.

If you want to learn more about how our platform supports better outcomes for diabetes, contact us today.